Profile data is unavailable for this security.
About the company
Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
- Revenue in USD (TTM)6.85m
- Net income in USD-157.35m
- Incorporated2020
- Employees72.00
- LocationCentessa Pharmaceuticals PLC3Rd Floor, 1 Ashley RoadALTRINCHAM WA14 2DTUnited KingdomGBR
- Websitehttps://www.centessa.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nurix Therapeutics Inc | 56.42m | -176.98m | 1.91bn | 284.00 | -- | 4.81 | -- | 33.93 | -2.91 | -2.91 | 0.9222 | 5.62 | 0.1373 | -- | -- | 198,676.10 | -43.07 | -33.01 | -52.51 | -39.66 | -- | -- | -313.65 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| MannKind Corp | 267.20m | 21.57m | 1.95bn | 414.00 | 99.55 | -- | 69.22 | 7.29 | 0.0711 | 0.0711 | 0.9277 | -0.7612 | 0.6812 | 2.79 | 13.36 | 645,410.60 | 5.50 | -26.07 | 7.00 | -37.80 | 71.91 | 59.68 | 8.07 | -57.61 | 4.17 | 1.89 | 1.77 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Fortrea Holdings Inc | 2.88bn | -228.20m | 1.97bn | 16.00k | -- | 1.34 | -- | 0.6838 | -2.56 | -3.23 | 32.30 | 16.33 | 0.7262 | -- | 3.48 | 159,794.40 | -5.76 | -- | -7.11 | -- | 17.17 | -- | -7.93 | -- | -- | -0.3374 | 0.4348 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Mirum Pharmaceuticals Inc | 307.03m | -99.81m | 2.02bn | 311.00 | -- | 8.74 | -- | 6.57 | -2.12 | -2.12 | 6.51 | 4.84 | 0.4657 | 3.83 | 5.28 | 1,162,985.00 | -15.14 | -38.93 | -17.70 | -44.88 | 72.68 | -- | -32.51 | -190.71 | 3.15 | -- | 0.5701 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -100.44m | 2.11bn | 136.00 | -- | 2.30 | -- | -- | -2.24 | -2.24 | 0.00 | 16.10 | 0.00 | -- | -- | 0.00 | -17.07 | -- | -17.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Recursion Pharmaceuticals Inc | 65.18m | -377.75m | 2.17bn | 500.00 | -- | 4.13 | -- | 33.33 | -1.53 | -1.53 | 0.2631 | 1.83 | 0.096 | -- | 24.06 | 130,368.00 | -55.66 | -- | -65.45 | -- | 35.07 | -- | -579.51 | -- | -- | -- | 0.0519 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| Centessa Pharmaceuticals PLC - ADR | 6.85m | -157.35m | 2.18bn | 72.00 | -- | 6.70 | -- | 318.60 | -1.56 | -1.56 | 0.0679 | 2.54 | 0.0173 | -- | 0.1817 | 90,171.05 | -39.75 | -- | -43.04 | -- | -- | -- | -2,296.03 | -- | -- | -- | 0.2105 | -- | -- | -- | 30.12 | -- | -- | -- |
| Akero Therapeutics Inc | 0.00 | -237.22m | 2.25bn | 60.00 | -- | 3.05 | -- | -- | -3.75 | -3.75 | 0.00 | 10.61 | 0.00 | -- | -- | 0.00 | -32.66 | -37.73 | -34.35 | -40.13 | -- | -- | -- | -- | -- | -- | 0.0454 | -- | -- | -- | -35.46 | -- | -- | -- |
| Azenta Inc | 658.62m | -156.38m | 2.25bn | 3.30k | -- | 1.16 | -- | 3.42 | -2.82 | -2.81 | 11.73 | 39.50 | 0.2443 | 3.08 | 3.49 | 188,176.30 | -5.80 | -0.5934 | -6.27 | -0.6725 | 39.78 | 43.08 | -23.74 | -2.17 | 4.21 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Beam Therapeutics Inc | 349.64m | -143.59m | 2.31bn | 436.00 | -- | 2.92 | -- | 6.62 | -1.72 | -1.72 | 4.27 | 9.58 | 0.284 | -- | -- | 801,933.50 | -11.67 | -24.54 | -13.84 | -29.26 | -- | -- | -41.07 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Wave Life Sciences Ltd | 110.50m | -73.74m | 2.31bn | 266.00 | -- | -- | -- | 20.94 | -0.5796 | -0.5796 | 0.9275 | 0.0359 | 0.5036 | -- | -- | 415,413.50 | -33.49 | -56.98 | -117.16 | -102.38 | -- | -- | -66.50 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -76.34m | 2.33bn | 50.00 | -- | 8.47 | -- | -- | -2.24 | -2.24 | 0.00 | 7.05 | 0.00 | -- | -- | 0.00 | -42.91 | -- | -46.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Geron Corp | 29.48m | -201.19m | 2.39bn | 141.00 | -- | 8.19 | -- | 81.18 | -0.3221 | -0.3221 | 0.0469 | 0.4846 | 0.0687 | -- | 1.31 | 209,078.00 | -46.90 | -51.32 | -63.81 | -64.90 | 97.29 | -- | -682.47 | -19,949.13 | 2.74 | -- | 0.2229 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| Scholar Rock Holding Corp | 0.00 | -203.85m | 2.41bn | 150.00 | -- | 15.96 | -- | -- | -2.22 | -2.22 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -79.66 | -38.14 | -89.70 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2726 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| SpringWorks Therapeutics Inc | 135.49m | -275.16m | 2.46bn | 305.00 | -- | -- | -- | 18.15 | -3.89 | -3.89 | 1.89 | -- | -- | -- | -- | 444,219.70 | -- | -36.97 | -- | -39.49 | 94.52 | -- | -203.09 | -2,176.46 | -- | -- | -- | -- | -- | -- | -17.19 | -- | 90.68 | -- |
Data as of Nov 13 2024. Currency figures normalised to Centessa Pharmaceuticals PLC's reporting currency: US Dollar USD
25.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 30 Jun 2024 | 5.71m | 4.45% |
| First Light Asset Management LLCas of 30 Jun 2024 | 4.78m | 3.72% |
| Perceptive Advisors LLCas of 30 Jun 2024 | 3.93m | 3.06% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Jun 2024 | 3.53m | 2.75% |
| Adage Capital Management LPas of 30 Jun 2024 | 3.13m | 2.43% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 2.79m | 2.17% |
| Octagon Capital Advisors LPas of 30 Jun 2024 | 2.35m | 1.82% |
| Invus Public Equities Advisors LLCas of 30 Jun 2024 | 2.11m | 1.64% |
| Driehaus Capital Management LLCas of 30 Jun 2024 | 2.09m | 1.63% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 2.05m | 1.59% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
